Aclarion Expands Nociscan Reach with Los Angeles Neuroscience Clinic Partnership
Event summary
- Aclarion partners with Institute of Neuro Innovation (INI) to expand Nociscan availability in Los Angeles.
- Agreement includes real-world evidence study comparing Nociscan biomarker data with SPECT-CT bone metabolic information.
- INI's neurosurgeon Amir Vokshoor, MD, will lead the integration of Nociscan into clinical practice.
- Nociscan demonstrates 97% surgical success rate when all Nociscan-positive discs are treated.
The big picture
Aclarion's partnership with INI aligns with its strategy to scale Nociscan's reach while building critical data assets. The collaboration addresses a significant market need—266 million people worldwide suffer from chronic low back pain—where current diagnostic tools often fall short. By integrating Nociscan with SPECT-CT, Aclarion aims to enhance treatment precision, potentially reshaping how chronic low back pain is diagnosed and managed.
What we're watching
- Adoption Dynamics
- How the INI partnership will accelerate Nociscan's adoption among neurosurgeons and pain specialists.
- Data Strategy
- Whether the real-world evidence generated will strengthen payer and provider acceptance.
- Competitive Positioning
- The pace at which Aclarion can differentiate Nociscan from existing diagnostic tools like MRI and SPECT-CT.
Related topics